Skip to main content
Clinical Trials/CTRI/2013/11/004147
CTRI/2013/11/004147
Other
Phase 4

Study to Assess the Dietary Carbohydrate Content of Indian Diabetics With Special Therapeutic View on Effectiveness of Acarbose and Metformin Monotherapy - STARCH AM

Bayer Zydus Pharma Private Ltd0 sites12,250 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: null- Type 2 diabetic patients
Sponsor
Bayer Zydus Pharma Private Ltd
Enrollment
12250
Status
Other
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Pms

Investigators

Sponsor
Bayer Zydus Pharma Private Ltd

Eligibility Criteria

Inclusion Criteria

  • Drug\-naïve (i.e., the patients should never be treated with anti\-diabetic drugs before screening) patients in whom decision to administer monotherapy with either acarbose or metformin for type\-2 diabetes management has been made by the attending physician on the basis of best clinical practice and medical patient needs, and who consent to participate in study will be included

Exclusion Criteria

  • Patients receiving any anti\-diabetic medication at the time of enrollment in the study will be excluded. However, during observation period, patients may receive any additional anti\-diabetics medication at the decision of investigator.
  • Exclusion criteria should be read in conjunction with local product information. All contra\-indications according to the local marketing authorization should be considered

Outcomes

Primary Outcomes

Not specified

Similar Trials